Issue 8, 2024

Optimization of lipid assisted polymeric nanoparticles for siRNA delivery and cancer immunotherapy

Abstract

To date, five siRNA-based medications have received clinical approval and have demonstrated remarkable therapeutic efficacy in treating various diseases. However, their application has been predominantly limited to liver-specific diseases due to constraints in siRNA delivery capabilities. In this study, we have developed a siRNA delivery system utilizing clinically approved mPEG-b-PLGA, a cationic lipid, and an ionizable lipid. We optimized this system by carefully adjusting their mass ratios, resulting in highly efficient gene silencing. Furthermore, the optimized nanoparticle formulation, which encapsulates siRNA targeting CD47, induces a robust immune response. This response effectively suppresses the progression of melanoma tumors by blocking this critical immune checkpoint.

Graphical abstract: Optimization of lipid assisted polymeric nanoparticles for siRNA delivery and cancer immunotherapy

Supplementary files

Article information

Article type
Paper
Submitted
20 12 2023
Accepted
26 2 2024
First published
12 3 2024

Biomater. Sci., 2024,12, 2057-2066

Optimization of lipid assisted polymeric nanoparticles for siRNA delivery and cancer immunotherapy

S. Lin, H. Jing, X. Du, X. Yang and J. Wang, Biomater. Sci., 2024, 12, 2057 DOI: 10.1039/D3BM02071A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements